Abstract:BACKGROUND Primary liver cancer is the sixth most common cancer worldwide, with hepatocellular carcinoma (HCC) being the most prevalent form. Despite the current availability of multiple immune or immune combination treatment options, the prognosis is still poor, so how to identify a more suitable population is extremely important. AIM To evaluate the clinical effectiveness of combining lenvatinib with camrelizumab for patients with hepatitis B virus (HBV)-related HCC in Barcelona Clinic Liver Cancer (BCLC) stages B/C, considering various body mass index (BMI) in different categories. METHODS Retrospective data were collected from 126 HCC patients treated with lenvatinib plus camrelizumab. Patients were divided into two groups based on BMI: The non-overweight group (BMI < 25 kg/m2, n = 51) and the overweight/obese group (BMI ≥ 25 kg/m2, n = 75). Short-term prognosis was evaluated using mRECIST criteria, with subgroup analyses for non-overweight (BMI: 18.5-24.9 kg/m2), overweight (BMI: 25-30 kg/m2), and obese (BMI ≥ 30 kg/m2) patients. A Cox proportional hazards regression analysis identified independent prognostic factors for overall survival (OS), leading to the development of a column-line graph model. RESULTS Median progression-free survival was significantly longer in the obese/overweight group compared to the non-overweight group. Similarly, the median OS was significantly prolonged in the obese/overweight group than in the non-overweight group. The objective remission rate and disease control rate for the two groups of patients were, respectively, objective remission rate (5.88% vs 28.00%) and disease control rate (39.22% vs 62.67%). Fatigue was more prevalent in the obese/overweight group, while other adverse effects showed no statistically significant differences (P > 0.05). Subgroup analysis based on BMI showed that obese and overweight patients had better progression-free survival and OS than non-overweight patients, with obese patients showing the best outcomes. Multifactorial regression analysis identified BCLC grade, alpha-fetoprotein level, portal vein tumor thrombosis, and BMI as independent prognostic factors for OS. The column-line graph model highlighted the importance of BMI as a major predictor of patient prognosis, followed by alpha-fetoprotein level, BCLC classification, and portal vein tumor thrombosis. CONCLUSION BMI is a long-term predictor of the efficacy of lenvatinib plus camrelizumab, and obese/overweight patients have a better prognosis.

Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma

BMI-1, a promising therapeutic target for human cancer.

Validation of Bmi1 As a Therapeutic Target of Hepatocellular Carcinoma in Mice.

BMI-1 activates hepatic stellate cells to promote the epithelial-mesenchymal transition of colorectal cancer cells

LncAY Controls BMI1 Expression and Activates BMI1/Wnt/β-catenin Signaling Axis in Hepatocellular Carcinoma

BMI1 Promotes the Progression of Laryngeal Squamous Cell Carcinoma.

BMI1 Promotes Cholangiocarcinoma Progression and Correlates with Antitumor Immunity in an Exosome-Dependent Manner

Overexpression of Bmi-1 Contributes to the Invasion and Metastasis of Hepatocellular Carcinoma by Increasing the Expression of Matrix Metalloproteinase (MMP)-2, MMP-9 and Vascular Endothelial Growth Factor Via the PTEN/PI3K/Akt Pathway

BMI1-induced CD127+KLRG1+ memory T cells enhance the efficacy of liver cancer immunotherapy

BMI-1 activates hepatic stellate cells to promote EMT of colorectal cancer cells

Targeting BMI-1-mediated epithelial-mesenchymal transition to inhibit colorectal cancer liver metastasis

Bmi1 Knockdown Inhibits Hepatocarcinogenesis.

Beneficial Body Mass Index to Enhance Survival Outcomes in Patients with Early-Stage Hepatocellular Carcinoma Following Microwave Ablation Treatment

BMI‐1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes

Bmi-1 Is Related To Proliferation, Survival And Poor Prognosis In Pancreatic Cancer

Impact of Baseline Body Mass Index on the Long-Term Prognosis of Advanced Hepatocellular Carcinoma Treated with Immunotherapy

Mechanistic Modeling of Gene Regulation and Metabolism Identifies Potential Targets for Hepatocellular Carcinoma

Cathepsin-facilitated Invasion of BMI1-high Hepatocellular Carcinoma Cells Drives Bile Duct Tumor Thrombi Formation

Integrated regulatory-metabolic network model reveals critical mechanism and potential targets for Hepatocellular Carcinoma

EZH2 Facilitates BMI1-dependent Hepatocarcinogenesis Through Epigenetically Silencing Microrna-200C

Nuclear Translocation of YAP Drives BMI1-associated Hepatocarcinogenesis in Hepatitis B Virus Infection